Skip to main content
H.R. 1672 119th Congress House

Maintaining Investments in New Innovation Act

Official title: To amend title XI of the Social Security Act to protect access to genetically targeted technologies.

Introduced: February 27, 2025 Introduced by: Donald G. Davis Democratic · North Carolina See on congress.gov
Health GeneticsMedicarePrescription drugs
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 27, 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Feb 27, 2025
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

What's happening now February 27, 2025

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

 Plain-English summary Congressional Research Service

Maintaining Investments in New Innovation Act

This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Lobbying activity 180

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

  • VENABLE LLP
    for ASSOCIATION OF BLACK CARDIOLOGISTS · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
  • BIOTECHNOLOGY INNOVATION ORGANIZATION
    for BIOTECHNOLOGY INNOVATION ORGANIZATION · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
  • VENABLE LLP
    for ASSOCIATION OF BLACK CARDIOLOGISTS · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
  • ALNYLAM PHARMACEUTICALS, INC.
    for ALNYLAM PHARMACEUTICALS, INC. · Massachusetts · 3rd Quarter 2026 (July 1 - Sep 30)
  • SPLITOAK STRATEGIES LLC
    for ALNYLAM PHARMACEUTICALS, INC. · Massachusetts · 3rd Quarter 2026 (July 1 - Sep 30)
  • AMGEN, INC.
    for AMGEN INC · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)

Bodies those filers lobbied

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

See all 180 filings →
 Cosponsors 51
R
Rulli, Michael A.
Ohio · Sep 24, 2026
D
Gonzalez, Vicente
Texas · Sep 4, 2026
R
Fitzpatrick, Brian K.
Pennsylvania · Aug 27, 2026
R
Carter, Earl L. "Buddy"
Georgia · Aug 10, 2026
D
Moskowitz, Jared
Florida · Aug 10, 2026
R
Evans, Gabe
Colorado · Jun 25, 2026
R
Langworthy, Nicholas A.
New York · Jun 18, 2026
R
Smith, Adrian
Nebraska · Jun 18, 2026
R
Smucker, Lloyd
Pennsylvania · Jun 18, 2026
R
Bilirakis, Gus M.
Florida · Apr 15, 2026
R
Barr, Andy
Kentucky · Mar 20, 2026
R
Lawler, Michael
New York · Jan 13, 2026
D
Mullin, Kevin
California · Dec 9, 2025
R
Hinson, Ashley
Iowa · Dec 4, 2025
R
Haridopolos, Mike
Florida · Nov 21, 2025
R
Kean, Thomas H.
New Jersey · Nov 21, 2025
R
Lee, Laurel M.
Florida · Nov 21, 2025
R
Moran, Nathaniel
Texas · Nov 17, 2025
R
Jack, Brian
Georgia · Nov 10, 2025
R
Fong, Vince
California · Nov 4, 2025
R
Calvert, Ken
California · Oct 31, 2025
R
Edwards, Chuck
North Carolina · Oct 31, 2025
R
Moolenaar, John R.
Michigan · Oct 31, 2025
R
Weber, Randy K. Sr.
Texas · Oct 31, 2025
R
Moore, Tim
North Carolina · Oct 17, 2025
R
Balderson, Troy
Ohio · Oct 3, 2025
R
Malliotakis, Nicole
New York · Sep 30, 2025
R
Meuser, Daniel
Pennsylvania · Sep 30, 2025
D
Pettersen, Brittany
Colorado · Sep 30, 2025
R
Fleischmann, Charles J. "Chuck"
Tennessee · Sep 17, 2025
R
Kelly, Mike
Pennsylvania · Sep 2, 2025
R
McDowell, Addison P.
North Carolina · Jun 10, 2025
R
Sessions, Pete
Texas · Jun 4, 2025
R
Pfluger, August
Texas · May 13, 2025
R
Shreve, Jefferson
Indiana · May 9, 2025
R
Carey, Mike
Ohio · Apr 10, 2025
R
Hern, Kevin
Oklahoma · Apr 9, 2025
R
Dunn, Neal P.
Florida · Mar 27, 2025
R
Allen, Rick W.
Georgia · Feb 27, 2025
R
Bean, Aaron
Florida · Feb 27, 2025
R
Crenshaw, Dan
Texas · Feb 27, 2025
D
Gottheimer, Josh
New Jersey · Feb 27, 2025
R
Hudson, Richard
North Carolina · Feb 27, 2025
R
Joyce, John
Pennsylvania · Feb 27, 2025
R
Miller-Meeks, Mariannette
Iowa · Feb 27, 2025
R
Moore, Blake D.
Utah · Feb 27, 2025
D
Morelle, Joseph D.
New York · Feb 27, 2025
D
Peters, Scott H.
California · Feb 27, 2025
R
Tenney, Claudia
New York · Feb 27, 2025
R
Van Duyne, Beth
Texas · Feb 27, 2025
Page 1 of 2 Next
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 1672: Maintaining Investments in New Innovation Act. 119th Congress. Open America. https://openamerica.io/bill/119-HR-1672/
MLA
"H.R. 1672: Maintaining Investments in New Innovation Act." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-HR-1672/.
Bluebook (legal)
H.R. 1672, 119th Cong. (2026), https://openamerica.io/bill/119-HR-1672/.
Markdown link
[H.R. 1672: Maintaining Investments in New Innovation Act](https://openamerica.io/bill/119-HR-1672/)
Report a problem